絞り込み

16547

広告

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).

著者 Jagannath S , Abonour R , Durie BGM , Gasparetto C , Hardin JW , Narang M , Terebelo HR , Toomey K , Wagner L , Srinivasan S , Kitali A , Yue L , Flick ED , Agarwal A , Rifkin RM
Clin Lymphoma Myeloma Leuk.2018 May 04 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (133view , 0users)

Full Text Sources

Medical

The treatment landscape for multiple myeloma (MM) has undergone recent changes with the regulatory approval of several new therapies indicated for second- and later-line disease. Using data from Connect MM, the largest multisite, primarily community-based, prospective, observational registry of MM patients in the United States, selection of second-line treatments was evaluated during a 5-year period from 2010 to 2016.
PMID: 29844008 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード